In Brief: Boston Scientific/Scimed
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific/Scimed: Federal Trade Commission requests additional information from the two companies regarding their proposed $865 mil. stock swap merger, which was announced in November ("The Gray Sheet" Nov. 14, 1994, p. 12). The additional information pertains to "the activities of the two companies in the area of intravascular ultrasound," the firms say in a joint statement. In September, Boston Scientific entered a definitive agreement to acquire IVUS system manufacturer Cardiovascular Imaging Systems in a deal valued at about $100 mil. Both Boston Scientific and Scimed have also been developing IVUS technology. The companies say that the FTC request is "not unusual for this type of transaction"...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.